Aug 14 (Reuters) - Mesoblast Ltd MSB.AX :
* ONCOLOGIC DRUGS ADVISORY COMMITTEE OF U.S. FDA VOTED IN FAVOR THAT AVAILABLE DATA SUPPORT EFFICACY OF REMESTEMCEL-L IN PEDIATRIC PATIENTS
Aug 14 (Reuters) - Mesoblast Ltd MSB.AX :
* ONCOLOGIC DRUGS ADVISORY COMMITTEE OF U.S. FDA VOTED IN FAVOR THAT AVAILABLE DATA SUPPORT EFFICACY OF REMESTEMCEL-L IN PEDIATRIC PATIENTS